Lippoldt Darin

CLO Lippoldt sells 4,376 NBIX shares at $159.65; retains 43,405 shares post-sale

Lippoldt, Neurocrine's Chief Legal Officer, sold 4,376 shares at $159.65 on December 8, 2025, reducing his holdings by 9.2%. The sale occurred at a price above the current trading level of $155.63 and well above the 52-week low of $87.54, suggesting execution near recent strength. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 4 prior sells, though his NBIX-specific history includes only 1 prior measurable outcome (the July 2024 sale, which showed -22.4% over 90 days). The company's fundamentals remain solid with $794.9M in latest quarterly revenue, net income of $209.5M, and 24.8% annual revenue growth, though the P/E of 36.28 reflects elevated valuation expectations. As a routine partial reduction in a profitable, growth-stage biopharmaceutical company, the sale does not signal material corporate distress or fundamental deterioration.

CLO Lippoldt sells 7,004 shares (7.0K) of NBIX at $150.00 for $1.1M; retains 39,740 shares.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, sold 7,004 shares at $150.00 on 2024-07-16, reducing his stake by 15.0% from 46,744 to 39,740 shares. At the transaction price of $150.00, the sale occurred near the 52-week high of $147.46, with the stock currently trading 2.2% below that peak. Looking at his prior sales of NBIX stock, Lippoldt's timing has been mixed: his December 2023 and November 2023 sales were followed by positive 90-day returns of 11.5% and 19.5% respectively, while his January 2024 sale saw a -5.6% return over 90 days. Across his broader cross-ticker trade history, his average 90-day return after sells is 8.5% with a 33.33% well-timed rate, but this does not necessarily predict outcomes at NBIX where only 1 of 3 prior sales has been well-timed at the 90-day mark.